Sanofi

Leland Stanford Junior University

Sanofi Biotechnology

Pieris Pharmaceuticals Gmbh

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Christian Lange

Ercole Rao

Gary J Nabel

Seng H Cheng

Sanjiv Sam Gambhir

Peter D Kwong

John R Mascola

Huawei Qiu

Christian Beil

Carsten Corvey

Jochen Kruip

Jochen Beninga

Nicolas Baurin

Ronnie Rong Wei

Francis Blanche

Tongqing Zhou

Ingo Focken

Zhi-Yong Yang

Wulf Dirk Leuschner

Thomas Langer

Vincent Mikol

Tarik Dabdoubi

Lan Wu

Gerhard Hessler

Christine Rothe

Andrea Allersdorfer

Marlon Hinner

Beatrice Cameron

Yunxiang Zhu

Alexander Wiedenmann

William Harold Brondyk

Kristian Hobolt Jensen

Timothy D Connors

Martin Lorenz

Cendrine Lemoine

Christian Engel

Bradley Lunde

Catherine Prades

Ling Xu

Anke Steinmetz

Danxi Li

Astrid Rey

Michael Mourez

Martin Hülsmeyer

Heike Stump

Katrin Lorenz

Béatrice Cameron

Mark Connors

Young Do Kwon

Edward Seung

Jinghe Huang

Katja Kroll

Wulf-Dirk Leuschner

Peter Wonerow

Sandra Weil

Laurent Fraisse

Hongmei Zhao

Hans-Falk Rasser

Mathias Gebauer

Yangde Chen

Catherine Devaud

Susanta K Sarkar

Dietmar Hoffmann

Peter Florian

Maureen Magnay

Tristan Magnay

Chirstian Biel

Dorothea Rat

Thomas Stuedemann

Leila Sevigny

Nadja Spindler

Soraya Hoelper

Bernard Calandra

Juergen Schaefer

Horst Blum

Richard H Kimura

Chantal Carrez

Mark Sommerfeld

Stéphanie Decary

Matthias Dreyer

Arutselvan Natarajan

Uwe Schwahn

Karl-Christian Engel

Marion Schneider

Werner Dittrich, I

Mangaiarkarasi Asokan

Amarendra Pegu

Christine Rudolph

Ohad Ilovich

David Papin

Richard A Koup

Sevim Ozgur Bruderle

Ronnie Wei

Ziyu Li

Soraya Hölper

Garima Tiwari

Jana Albrecht

Jennifer Jung

Cédric Barriere

Stéphane Guerif

Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof), or the use of the conjugate in medicine.

FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides

An antibody that specifically binds to IL-1R3, comprising an antibody heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. A pharmaceutical composition is provided comprising the said antibody and a pharmaceutically acceptable diluent, carrier or excipient. Also said antibody for use in treating a disease or disorder in a subject in need thereof. The disease or disorder may be an autoimmune or autoinflammatory disease or disorder.

Humanized anti-IL-1R3 antibody and methods of use

Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

Multispecific binding proteins with mutant fab domains

The disclosure provides trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation and wherein a second pair of polypeptides forming the binding protein possess a single variable domain. The disclosure also provides methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific and/or trivalent binding proteins

Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.

Multispecific antibodies facilitating selective light chain pairing

Provided herein are bivalent, bispecific binding proteins that specifically bind to two different HIV-1 Env protein epitopes.

Bivalent, bispecific binding proteins for prevention or treatment of HIV infection

Binding proteins comprising a pseudoFab domain including a stabilised knockout domain and a second VH/VL that form a first functional antigen binding domain are provided. Multispecific binding proteins comprising at least one pseudoFab are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

PseudoFab-based multispecific binding proteins

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Multispecific binding molecules having specificity to dystroglycan and laminin-2

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth ofand/or to prevent or treatbiofilm infection as well as diseases or disorders associated withbiofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Fusion molecules

The present invention concerns antibody-like binding protein specifically binding to CD3 and binding specifically to at least one further antigen, for example CD123. The present invention also concerns antibody-like binding protein specifically binding to CD123 and binding specifically to at least one further antigen. The invention further concerns anti-CD3 antibodies and anti-CD123 antibodies. The invention also relates to pharmaceutical compositions comprising the antibody-like binding protein, anti-CD3 antibodies or anti-CD123 antibodies of the invention, and their use to treat cancer. The invention further relates to isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibody-like binding protein, anti-CD3 or anti-CD123 antibody and the use of said anti-CD123 antibody as a diagnostic tool.

Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123

Growing community of inventors

Frankfurt am Main, Germany

Christian Lange